Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylate

Closes 18 May 2021

Opened 6 Apr 2021

Overview

The Therapeutic Goods Administration (TGA) is seeking comments from interested parties on proposed new advisory statements for labels of over the counter (OTC) and registered complementary medicines containing methyl salicylate for dermal use, for inclusion in the Required Advisory Statements for Medicine Labels (RASML). The proposal to include advisory statements for methyl salicylate-containing medicines in RASML follows previously implemented requirements for advisory statements on labels of methyl salicylate-containing listed medicines.

Why we are consulting

The TGA is requesting comments that will help ensure that the proposed advisory statements are appropriate and support the quality use of the medicines and that any label changes that would be required for these medicines are made in the most convenient, efficient and cost-effective way.

Consultation paper

Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Methyl salicylate

Providing feedback

We invite you to provide your feedback by clicking 'Make a submission' below and responding to the consultation question (by free text and/or file upload).

Have your say

Audiences

  • Academics
  • Non-government organisations
  • State government agencies
  • Commonwealth agencies
  • Health professionals
  • General public
  • Community groups
  • HPRG (TGA) Staff
  • Complementary medicines
  • Over-the-counter medicines

Interests

  • Non-prescription medicines